Phio Pharmaceuticals Corp. Files S-1

TL;DR

Phio Pharma filed an S-1, check financials and future plans.

AI Summary

Phio Pharmaceuticals Corp. filed an S-1 form on January 21, 2025, detailing its financial status and business operations. The company, formerly known as RXi Pharmaceuticals Corp. until October 19, 2011, is incorporated in Delaware and operates in the pharmaceutical preparations sector. Its principal executive offices are located at 11 Apex Drive, Suite 300A, Marlborough, MA.

Why It Matters

This S-1 filing provides crucial information for investors and the public regarding Phio Pharmaceuticals Corp.'s financial health, strategic direction, and potential future offerings.

Risk Assessment

Risk Level: medium — As a pharmaceutical company filing an S-1, there are inherent risks associated with drug development, regulatory approvals, and market competition.

Key Numbers

• 2834 — SIC Code (Indicates the company operates in Pharmaceutical Preparations)
• 333-284381 — SEC File Number (Unique identifier for the filing)

Key Players & Entities

• Phio Pharmaceuticals Corp. (company) — Filer of the S-1 document
• RXi Pharmaceuticals Corp. (company) — Former name of Phio Pharmaceuticals Corp.
• 11 Apex Drive, Suite 300A, Marlborough, MA (location) — Business and mailing address
• 20250121 (date) — Filing date of the S-1

FAQ

Key Financial Figures

• $0.0001 — " " we ," " us " or " our "), par value $0.0001 per share (the " Common Stock ) consist
• $17.5 million — n gross proceeds to us of approximately $17.5 million. However, we cannot predict when and in
• $2.77 — Stock on The Nasdaq Capital Market was $2.77 per share. Investing in our securities
• $4 million — we had agreed to reimburse AgonOx up to $4 million in expenses incurred to conduct a Phase
• $35,000 — ade to AgonOx as of Sept 30, 2024 total $35,000, which primarily relate to accrued obli
• $2.635 — of Common Stock at a purchase price of $2.635 per share. In the December 19, 2024 Pri
• $2.51 — arrant Share ") at an exercise price of $2.51 per share and will expire on December 2
• $0.125 — offered and sold at a purchase price of $0.125 per Series E Warrant, which purchase pr
• $2.00 — of common stock at a purchase price of $2.00 per share. In the December 23, 2024 Pri
• $3.00 — of common stock at a purchase price of $3.00 per share. In the January 13, 2025 Priv

Filing Documents

• phio_s1.htm (S-1) — 1325KB
• phio_ex0501.htm (EX-5.1) — 8KB
• phio_ex2301.htm (EX-23.1) — 2KB
• phio_ex107.htm (EX-FILING FEES) — 39KB
• image_001.jpg (GRAPHIC) — 4KB
• image_002.jpg (GRAPHIC) — 16KB
• image_003.jpg (GRAPHIC) — 3KB
• image_004.jpg (GRAPHIC) — 2KB
• 0001683168-25-000460.txt ( ) — 4252KB
• phio-20240930.xsd (EX-101.SCH) — 27KB
• phio-20240930_cal.xml (EX-101.CAL) — 32KB
• phio-20240930_def.xml (EX-101.DEF) — 112KB
• phio-20240930_lab.xml (EX-101.LAB) — 270KB
• phio-20240930_pre.xml (EX-101.PRE) — 217KB
• phio_s1_htm.xml (XML) — 392KB

Use of Proceeds

Use of Proceeds 21 DIVIDEND POLICY 21 DETERMINATION OF OFFERING PRICE 21 MARKET INFORMATION 21 HOLDERS 21

Management's discussion and analysis

Management's discussion and analysis 29 Management 39 DIRECTOR AND EXECUTIVE OFFICER COMPENSATION 42

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT

SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT 46 SELLING STOCKHOLDERS 48 PLAN OF DISTRIBUTION 50

DESCRIPTION OF SECURITIES TO BE REGISTERED

DESCRIPTION OF SECURITIES TO BE REGISTERED 52 LEGAL MATTERS 54 EXPERTS 54 Where You Can Find More Information 54 INDEX TO FINANCIAL STATEMENTS 55 ABOUT THIS PROSPECTUS This prospectus relates to the resale by the Selling Stockholders identified in this prospectus under the caption " Selling Stockholders ," from time to time, of up to an aggregate of 5,930,016 shares of Common Stock. We are not selling any shares of Common Stock under this prospectus, and we will not receive any proceeds from the sale of shares of Common Stock offered hereby by the Selling Stockholders, although we may receive cash from the exercise of the Warrants. You should rely only on the information provided in this prospectus. We have not authorized anyone to provide you with any other information and we take no responsibility for, and can provide no assurances as to the reliability of, any other information that others may give you. The information contained in this prospectus speaks only as of the date set forth on the cover page and may not reflect subsequent changes in our business, financial condition, results of operations and prospects. We are not, and the Selling Stockholders are not, making offers to sell these securities in any jurisdiction in which an offer or solicitation is not authorized or permitted or in which the person making such offer or solicitation is not qualified to do so or to any person to whom it is unlawful to make such an offer or solicitation. You should read this prospectus in its entirety before making an investment decision. You should also read and consider the information in the documents to which we have referred you in the section entitled " Where You Can Find More Information " below, including the registration statement and the other reports we file with the SEC. In this prospectus, unless otherwise noted, (1) the term "Phio" refers to Phio Pharmaceuticals Corp. and our subsidiary, MirImmune, LLC and (2) the terms "Company," "we," "us"

View Full Filing

View this S-1 filing on SEC EDGAR